Blaas- en urinewegentumoren
TAR-210 MoonRISE-3
A phase 3, randomized study evaluating the efficacy and safety of TAR-210 Erdafitinib intravesical delivery system vs. intravesical chemotherapy in participants with High-risk Non-muscle-invasive Bladder Cancer with susceptible FGFR alterations who received intravesical BCG
- Inclusion criteria: Papillary-only HR-NMIBC (defined as HG Ta or any T1, no CIS), susceptible FGFR mutation (urine of tissue), recurrence within 12 months after BCG
- Exclusion criteria: Presence of CIS, UC or histological variant at any site outside of the urinary bladder, N+ and/or M+ per BICR of CT/MR Urography
- Investigator: prof. dr. Ben Van Cleynenbreugel
- Sub-investigator (Urology): dr. Carl Van Haute
- More information: NCT06919965
EFFORT Trial
Phase II prospective trial to evaluate the impact of 18FFDG-PET-CT in stratifying patients with primary muscle invasive bladder cancer and adapting the treatment accordingly.
- Inclusion criteria: Patients diagnosed with muscle invasive bladder cancer without distant metastasis on conventional imaging (CT chest, abdomen and pelvic MRI) and who are candidates for neoadjuvant chemotherapy and radical curative treatment.
- Local site Principal Investigator (Urology): prof. dr. Maarten Albersen
- Sub-investigator (Nuclear Medicine): prof. dr. Karolien Goffin
- Sub-investigator (Radiotherapy): prof. dr. Gert De Meerleer
- More information: dr. Loïc Baekelandt (PhD) via loic.baekelandt@uzleuven.be or 016 344722
SINCERE Registry
Effect of a single instillation of Mitomycin C on the intravesical recurrence rate after ureteroscopy for Upper Tract Urothelial Carcinoma: A prospective, multicenter registry study.
- Inclusion criteria: All patients ≥ 18 years old with clinically non-metastatic UTUC planned for URS, either as a diagnostic or as treatment, followed by a SI-MMC (or any equivalent) are eligible for this study.
- Local site Principal Investigator: dr. Carl Van Haute
- More information: NCT05731622
Niertumoren
Er zijn momenteel geen studies beschikbaar.
Penistumoren
Er zijn momenteel geen studies beschikbaar.
Prostaattumoren
Er zijn momenteel geen studies beschikbaar.
Testistumoren
Er zijn momenteel geen studies beschikbaar.
Urinaire incontinentie
NEMISIS
Sacral neuromodulation as treatment for voiding dysfunction in multiple sclerosis patients.
- Inclusion criteria: Diagnosis of Multiple Sclerosis according the McDonald criteria, stable relapsing remitting MS, EDSS 0-6, storage LUTD with Urgency Frequency or Urgency Urinary Incontinence.
- Local site Principal Investigator: prof. dr. Frank Van der Aa
- Sub-investigator (Urology): dr. Lisa Moris
- More information: urologie.trial@uzleuven.be
Urineweg-infecties
MINUS Trial
Multicentric study on Infections of the Urinary tract after Stent removal
- Inclusion criteria: Patients, 18 years of age and older who receive a ureteral stent during any endoscopic procedure will be approached to participate in the study
- Local site Principal Investigator: dr. Carl Van Haute
- Sub-investigator (Urology): prof. dr. Ben Van Cleynenbreugel
- More information: NCT05329883
Zelfkatheterisatie
EVA studie
Study of Colopast catheter selection criteria at start of self-catheterisation
- Inclusion criteria: patients with neurogenic or non-neurogenic bladder issues, justifying the implementation of intermittent self-catheterisation (ISC) to clean out the bladder, for at least 6 months
- Local site Principal Investigator: prof. dr. Frank Van Der Aa
- Sub-investigator: dr. Lisa Moris
- More information: NCT05065255
Questions
For more information, please contact trial urology.
- Email: urologie.trial@uzleuven.be
- Phone: +3216348345